173 Folgen

  1. Ep115: Rahul Singhvi on Reimagining Biotech Manufacturing

    Vom: 7.6.2022
  2. Ep114: Chris Gibson on Industrializing Drug Discovery

    Vom: 23.5.2022
  3. Ep113: Lewis Cantley & Siddhartha Mukherjee on Fighting Cancer with Food and Drugs

    Vom: 9.5.2022
  4. Ep112: Bernat Olle on Microbiome Therapeutics

    Vom: 18.4.2022
  5. Ep111: Ray Stevens on Structural Biology-Driven Drug Discovery

    Vom: 14.3.2022
  6. Ep110: Michele Andrasik on Making Clinical Trials More Diverse

    Vom: 1.3.2022
  7. Ep109: Derrell Porter on Cell Therapy Commercialization

    Vom: 15.2.2022
  8. Ep108: Praveen Tipirneni on Targeting Integrins With Small Molecules

    Vom: 31.1.2022
  9. Ep107: Bassil Dahiyat on Antibody Engineering & Company Building

    Vom: 11.1.2022
  10. Ep106: Vineeta Agarwala on Health Data & VC Investing

    Vom: 20.12.2021
  11. Ep105: Nello Mainolfi on Targeted Protein Degraders

    Vom: 6.12.2021
  12. Ep104: Jeff Bluestone on Treg Cell Therapies for Autoimmunity

    Vom: 1.12.2021
  13. Ep103: Ken Song on Targeted Radiopharmaceuticals for Cancer

    Vom: 23.11.2021
  14. Ep102: David Baltimore Reflects on a Life in Science

    Vom: 8.11.2021
  15. Ep101: Tony Kulesa on Fostering Founder-Led Biotechs

    Vom: 26.10.2021
  16. Ep100: Christian Henry on Long Read DNA Sequencing

    Vom: 13.10.2021
  17. Ep99: Keolu Fox on Genome Sequencing of Indigenous Populations

    Vom: 27.9.2021
  18. Ep98: Mara Aspinall on Diagnostics and COVID-19

    Vom: 13.9.2021
  19. Ep97: John Evans on Base Edited Therapeutics

    Vom: 7.9.2021
  20. Ep96: Julie Grant and Sam Blackman on Cancer Drugs for Kids

    Vom: 9.8.2021

4 / 9

"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Visit the podcast's native language site